Mechanism of Action

divider-mb

RYBREVANT® is a bispecific antibody that binds to the extracellular domains of EGFR and MET and disrupts EGFR and MET signaling functions through1:

  • Blocking ligand binding, and degradation of EGFR and MET1
MOA
  • Antibody-dependent cellular cytotoxicity and trogocytosis​1
MOA

EGFR, epidermal growth factor receptor; MET, Mesenchymal-Epithelial Transition.

Explore

cnt-divider

insertionlogo

EGFR Exon 20 Insertion Mutations

Learn about EGFR exon 20
insertion mutations.

Learn more

efficacylogo

Efficacy

Explore the results from the
CHRYSALIS trial.

Learn more

safetylogo

Safety

Review the safety profile
of RYBREVANT®.

Learn more

register

Register for Updates

Sign up to receive the latest news and information about RYBREVANT® by completing the registration form.

Reference

1. RYBREVANT® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.